Publications

Article

Incidence and Preventability of Adverse Drug Events in the Nursing Home Setting

By: J. H. Gurwitz, T. S. Field, J. Avorn, D. McCormick, S. Jain, M. Eckler, M. Benser, A. Edmondson and D. W. Bates

Keywords: Health; Health Industry

Find at Harvard

December 1999 (Revised August 2001)
Case

Millennium Pharmaceuticals, Inc. (A)

By: Stefan H. Thomke and Ashok Nimgade

Focuses on Millennium's strategy to grow and revolutionize drug development through the use of new technologies such as genomics. Describes how Millennium Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used strategic alliances to finance the... View Details

Keywords: Cost Management; Financing and Loans; Medical Specialties; Retention; Growth and Development Strategy; Time Management; Product Development; Problems and Challenges; Alliances; Technology; Biotechnology Industry; Pharmaceutical Industry; Cambridge

December 1999 (Revised February 2001)
Case

CVS: The Web Strategy

By: John A. Deighton and Anjali C. Shah

How should America's second-largest pharmacy chain respond to the challenge from online drugstores? What threat does the web pose to bricks and mortar distribution of prescription drugs and the other items that make up 50% of a drugstore's sales? This case describes... View Details

Keywords: Leveraged Buyouts; Marketing Channels; Distribution Channels; Service Operations; Corporate Strategy; Pharmaceutical Industry; Web Services Industry

1999
Chapter

The Economics of Drug Discovery

By: Rebecca M. Henderson and Iain Cockburn

Keywords: Economics; Innovation and Invention; Research and Development; Pharmaceutical Industry

Read Now

June 1999 (Revised October 1999)
Case

Eli Lilly, 1998 (A): Strategic Challenges

By: Michael Y. Yoshino and Thomas W. Malnight

Deals with key strategic challenges facing Eli Lilly, a highly successful U.S.-based drug company. View Details

Keywords: Problems and Challenges; Strategy; Pharmaceutical Industry

June 1999 (Revised June 2000)
Case

Eckerd Corporation

By: Michael E. Porter and John E. Kelleher

Describes the history and current situation in the retail pharmacy industry, including competition from new merchants and Internet drugstores. Eckerd, one of the top four drug chains, must decide how to position itself for the future. View Details

Keywords: Competition; Alignment; Supply and Industry; Retail Industry; Pharmaceutical Industry

March 1999 (Revised June 2000)
Case

Eli Lilly: The Evista Project

By: Steven C. Wheelwright and Matt Verlinden

Describes the creation and operation of the initial two heavyweight teams for new drug development and launch. The primary focus is on one of the teams, Evista, although comparisons to the other team, Zyprexa, are included. Lilly must decide the next phase (postlaunch)... View Details

Keywords: Projects; Groups and Teams; Operations; Management Teams; Product Development; Transition; Product Design; Business Startups; Business Plan; Product Launch; Competition; Service Operations; Pharmaceutical Industry

January 1999
Background Note

Note on the Drugstore Industry

By: David E. Bell and Ann Leamon

In response to the twin pressures of cross-channel competition and the prevalence of third-party drug plans, drugstores have changed both how they go to market and what they offer once they get there. This note reviews the history of drugstores, presents the current... View Details

Keywords: History; Industry Growth; Retail Industry; Pharmaceutical Industry

Article

Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery

By: Rebecca M. Henderson and Iain Cockburn

Keywords: Behavior; Research and Development; Organizations; Health

Find at Harvard

Read Now

May 1998
Background Note

Pharma Giants,The: Ready for the 21st Century?

By: Robert H. Hayes and Perry Fagan

Presents the changing competitive dynamics in the global pharmaceutical industry and possible implications for large drug companies. View Details

Keywords: Transformation; Globalized Firms and Management; Competition; Pharmaceutical Industry

Find at Harvard

April 1998
Case

Cephalon, Inc.

By: Peter Tufano

In early 1997, Cephalon, awaited an FDA panel's decision on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might need substantial additional funds to commercialize as well as to buy back rights to it (which had been sold earlier to... View Details

Keywords: Risk Management; Financing and Loans; Health Care and Treatment; Pharmaceutical Industry; United States

February 1998 (Revised March 2003)
Teaching Note

Eli Lilly and Company: Drug Development Strategy (A) and (B) TN

By: Stefan H. Thomke and Ashok Nimgade

Teaching Note for (9-698-010) and (9-698-026). View Details

February 1998 (Revised October 1998)
Background Note

Note on New Drug Development in the United States

By: Stefan H. Thomke and Ashok Nimgade

An overview of the new drug development process in the United States, using the migraine drug Imitrex as an illustrative example. View Details

Keywords: Product Development; Research and Development; Health; Pharmaceutical Industry; United States

December 1997 (Revised September 2002)
Supplement

Eli Lilly and Company: Drug Development Strategy (B)

By: Stefan H. Thomke and Ashok Nimgade

Supplements the (A) case. View Details

October 1997 (Revised September 2003)
Case

Eli Lilly and Company: Drug Development Strategy (A)

By: Stefan H. Thomke, Ashok Nimgade and Paul Pospisil

Describes how Eli Lilly and Co. tries to accelerate its new drug development process with the aid of "combinatorial chemistry"--a rapidly emerging and revolutionary approach to preclinical drug discovery. The product manager of a potential blockbuster migraine drug... View Details

Keywords: Chemicals; Finance; Innovation and Invention; Time Management; Markets; Product Development; Organizations; Business Processes; Problems and Challenges; Business and Stakeholder Relations; Competition; Pharmaceutical Industry